Medicare National Coverage Determinations (NCD) Manual (Pub. 100-03), Ch. 1 § 20.21

Chelation Therapy for Treatment of Atherosclerosis

Last amended: 2003Year: 2003Length: 155 wordsOfficial source
20.21 - Chelation Therapy for Treatment of Atherosclerosis (Rev. 1, 10-03-03) CIM 35-64 Chelation therapy is the application of chelation techniques for the therapeutic or preventive effects of removing unwanted metal ions from the body. The application of chelation therapy using ethylenediamine-tetra-acetic acid (EDTA) for the treatment and prevention of atherosclerosis is controversial. There is no widely accepted rationale to explain the beneficial effects attributed to this therapy. Its safety is questioned and its clinical effectiveness has never been established by well-designed, controlled clinical trials. It is not widely accepted and practiced by American physicians. EDTA chelation therapy for atherosclerosis is considered experimental. For these reasons, EDTA chelation therapy for the treatment or prevention of atherosclerosis is not covered. Some practitioners refer to this therapy as chemoendarterectomy and may also show a diagnosis other than atherosclerosis, such as arteriosclerosis or calcinosis. Claims employing such variant terms should also be denied under this section. Cross-reference: §20.22.
Medicare National Coverage Determinations (NCD) Manual (Pub. 100-03), Ch. 1 § 20.21: Chelation Therapy for Treatment of Atherosclerosis | Justis AI